For most of their young lives, Jenna and Patrick Partington have lived by the alarm clock — seven foul-tasting pills at 7 a.m., then again at 11 a.m., 7 p.m. and 11 p.m
Lindsay Porter’s kidneys weighed 16 pounds before her transplant. STORY HIGHLIGHTS (CNN) — By the time Lindsay Porter had her kidneys removed two years ago, they were bulging — covered in cysts — and together weighed 16 pounds. Her abdominal area was so distended, “I looked nine months pregnant, and people regularly asked when I was due,” Porter said.
Editor's Choice Academic Journal Main Category: Genetics Article Date: 21 Feb 2012 – 10:00 PST email to a friend printer friendly opinions Current Article Ratings: Patient / Public: Healthcare Prof: Fibrosis is a harmful build-up of excessive fibrous tissue that results in scarring, and ultimately, the loss of organ function. Although it can affect any tissue and organ system, it is most common in the heart, liver, lung, peritoneum, and kidney.
LA JOLLA, Calif., Feb. 16, 2012 /PRNewswire/ — Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that new preclinical data investigating the role of microRNA-21 (miR-21) in the treatment of kidney fibrosis has been published in the journal Science Translational Medicine
CAMBRIDGE, Mass., Feb. 16, 2012 (GLOBE NEWSWIRE) — Pathfinder Cell Therapy, Inc. (“Pathfinder,” or “the Company”) (OTCQB:PFND.PK – News), a biotechnology company focused on the treatment of diseases characterized by organ-specific cell damage, today announced that Richard L.
CAMBRIDGE, Mass., Feb. 15, 2012 (GLOBE NEWSWIRE) — Pathfinder Cell Therapy, Inc. (“Pathfinder,” or “the Company”) (OTCQB:PFND.PK – News), a biotechnology company focused on the treatment of diseases characterized by organ-specific cell damage, today announced that the European Patent Office (EPO) has communicated its intent to grant Pathfinder's first European Patent, EP1896571, which provides intellectual property protection for the Company's cell-based technology throughout this region.
Public release date: 14-Feb-2012 [ | E-mail | Share ] Contact: Joseph Caspermeyer Joseph.Caspermeyer@asu.edu Arizona State University Blood tests have been a mainstay of diagnostic medicine since the late 19th century, offering a wealth of information concerning health and disease.
Juventas Therapeutics is a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease. The Company's lead product, JVS-100, encodes Stromal cell-Derived Factor 1 (SDF-1) which has been shown to repair damaged tissue through recruitment of circulating stem cells to the site of injury, prevention of ongoing cell death and restoration of …
15-01-2012 06:04 * The BEST Way to protect against cancer and very bad diseases is NATURE. * PREVENTION and BEING IN NATURE HARMONY are The First Things to do
An open-label study of rituximab, a monoclonal antibody for human CD20, was shown to be safe in patients with primary biliary cirrhosis (PBC) who had an incomplete response to the standard ursodeoxycholic acid (UDCA) therapy, also known as Ursodiol.
The European Society of Cardiology (ESC) welcomes an “intriguing” study, published today in the Journal of the American College of Cardiology, featuring a completely novel approach for improving endothelial function in heart failure.
10-09-2011 19:18 www.rhemat.stemtechbiz.com e mail chris@rhemat.co.za The Roll of Stem Cells in your Body Support the Natural Healing System of the Body